SLU-PP-332: A Research Overview

SLU-PP-332 is one of the newest and most-hyped entries in the “exercise mimetic” space — a compound studied for its ability to switch on some of the same cellular programs that endurance exercise activates. The science behind it is legitimately interesting, but two clarifications are essential and often misunderstood: it is not a peptide (despite being marketed as one in some places), and the evidence is entirely preclinical — mouse and cell studies, with no human data and no approval. An honest overview presents the intriguing mechanism while being firm about both points.

This overview summarizes what the published literature reports about SLU-PP-332 — its nature, mechanism, the preclinical evidence, and status. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What SLU-PP-332 Is — and Is Not

First, an important correction often seen in product listings: SLU-PP-332 is not a peptide. It is a synthetic small molecule — an agonist of estrogen-related receptor alpha (ERRα), a nuclear receptor. Some vendors label it an “oral peptide,” which is inaccurate; it is a small-molecule drug-like compound (SLU-PP-332 as a synthetic ERRα agonist (not a peptide)). It was identified and characterized as a novel ERRα agonist in medicinal-chemistry research (identification and characterization of SLU-PP-332).

Mechanism — ERRα and the Exercise Program

SLU-PP-332 activates ERRα, a master transcriptional regulator of energy metabolism. ERRα — working with the coactivator PGC-1α — controls genes governing oxidative metabolism, mitochondrial biogenesis, and energy production. By turning on ERRα, SLU-PP-332 induces in skeletal muscle a genetic program resembling that triggered by acute aerobic exercise and enhances mitochondrial function and cellular respiration (ERRα-dependent exercise gene program and mitochondrial respiration). This is the basis for the “exercise mimetic” label — the idea of capturing some molecular adaptations of endurance training pharmacologically.

The Evidence Base — Entirely Preclinical

The SLU-PP-332 evidence is preclinical. In the foundational work, the compound induced an ERRα-dependent exercise gene signature and improved endurance and exercise capacity in mice, and increased oxidative (type IIa) muscle fibers (mouse endurance / exercise-capacity findings). Subsequent cell and pilot studies have explored ERR activation to mitigate muscle atrophy and aging-related muscle changes, reporting effects on markers such as PGC-1α, SIRT1, and FNDC5 in muscle cell models (ERR-targeting in age-related muscle atrophy (pilot/cell study)). The decisive limitation: there are no human clinical trials of SLU-PP-332. All efficacy claims rest on animal and cell data, and the authors of the muscle-atrophy work themselves note that further study is needed to clarify mechanisms. “Exercise in a pill” remains a research hypothesis, not a demonstrated human result.

• Synthetic small-molecule ERRα agonist — NOT a peptide, despite some product labeling.
• Activates ERRα/PGC-1α to induce an exercise-like gene program and mitochondrial biogenesis.
• Evidence is entirely preclinical (mouse/cell); no human trials; not approved.

Safety and Status

The status below reflects mid-2026 and may change; verify before relying on it. SLU-PP-332 is not FDA-approved for any indication and is an early-stage research compound; it is reported as in development / not yet available for clinical use (development-stage / not available status). Because there are no human studies, its human safety profile is essentially uncharacterized — an important caution in itself. As a manipulator of a master metabolic regulator, it warrants careful study that has not yet been done in people. Research-grade material is sold for laboratory use only and, by its labeling, is not for human consumption.

Why SLU-PP-332 Draws Research Interest

SLU-PP-332 is a notable proof-of-concept in exercise-mimetic research — a small molecule that activates ERRα to reproduce, in mice, parts of the molecular response to endurance exercise, with potential relevance to metabolic disease and muscle aging. The accurate framing is that it is a synthetic ERRα agonist (not a peptide) with intriguing but entirely preclinical evidence, no human data, an uncharacterized human safety profile, and no approval.

For deeper reading, the cited primary research is the best starting point. As a metabolic/mitochondrial research compound, it sits near others in this library — see the 5-Amino-1MQ, MOTS-c, and SS-31 overviews. The wider class is collected in our peptide research library.